Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Same-Slide Spatial Multi-Omics Integration Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.
Yeo YY, Chang Y, Qiu H, Yiu SPT, Michel HA, Wu W, Jin X, Kure S, Parmelee L, Luo S, Cramer P, Lee JL, Wang Y, Yeung J, Ahmar NE, Simsek B, Mohanna R, Orden MV, Lu W, Livak KJ, Li S, Shahryari J, Kingsley L, Al-Humadi RN, Nasr S, Nkosi D, Sadigh S, Rock P, Frauenfeld L, Kaufmann L, Zhu B, Basak A, Dhanikonda N, Chan CN, Krull J, Cho YW, Chen CY, Lee JYJ, Wang H, Zhao B, Loo LH, Kim DM, Schurch CM, Shalek AK, Boussiotis V, Zhang B, Howitt B, Signoretti S, Hodi FS, Burack WR, Rodig SJ, Ma Q, Jiang S. Yeo YY, et al. Among authors: hodi fs. bioRxiv [Preprint]. 2024 Dec 22:2024.12.20.629650. doi: 10.1101/2024.12.20.629650. bioRxiv. 2024. PMID: 39764057 Free PMC article. Preprint.
Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
Huang RY, Youssef G, Nelson T, Wen PY, Forsyth P, Hodi FS, Margolin K, Algazi AP, Hamid O, Lao CD, Ernstoff MS, Moschos SJ, Atkins MB, Postow MA, Reardon DA, Grootendorst DJ, Leung D, Askelson M, Ritchings C, Tawbi HA. Huang RY, et al. Among authors: hodi fs. J Clin Oncol. 2025 Jan 3:JCO2400953. doi: 10.1200/JCO.24.00953. Online ahead of print. J Clin Oncol. 2025. PMID: 39752606
Cigarette smoking and symptom burden: baseline results from 9 ECOG-ACRIN cancer clinical trials.
Price SN, Lee JW, Gareen IF, Kircher SM, Kumar SK, Mayer IA, Saba NF, Fenske TS, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Park ER, Wagner LI. Price SN, et al. Among authors: hodi fs. J Pain Symptom Manage. 2024 Dec 31:S0885-3924(24)01233-8. doi: 10.1016/j.jpainsymman.2024.12.021. Online ahead of print. J Pain Symptom Manage. 2024. PMID: 39746495
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab.
Chen J, Tarantino G, Severgnini M, Baginska J, Giobbie-Hurder A, Weirather JL, Manos M, Russell JD, Pfaff KL, Rodig SJ, Huang AY, Brennick R, Nazzaro M, Hathaway E, Holovatska M, Manuszak C, Ranasinghe S, Liu D, Hodi FS. Chen J, et al. Among authors: hodi fs. Oncoimmunology. 2025 Dec;14(1):2432723. doi: 10.1080/2162402X.2024.2432723. Epub 2024 Dec 19. Oncoimmunology. 2025. PMID: 39699928 Free PMC article.
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Tawbi HA, et al. Among authors: hodi fs. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Online ahead of print. J Clin Oncol. 2024. PMID: 39671533
Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients.
Robert C, Long GV, Larkin J, Wolchok JD, Hassel JC, Schadendorf D, Hodi FS, Lebbé C, Grob JJ, Hyngstrom JR, Wagstaff J, Chesney J, Butler MO, Bechter O, Márquez-Rodas I, Pavlick AC, Durani P, Pe Benito M, Wang P, Postow MA, Ascierto PA. Robert C, et al. Among authors: hodi fs. Eur J Cancer. 2025 Jan;214:115119. doi: 10.1016/j.ejca.2024.115119. Epub 2024 Nov 16. Eur J Cancer. 2025. PMID: 39612757 Free article.
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
Tarantino G, Ricker CA, Wang A, Ge W, Aprati TJ, Huang AY, Madha S, Chen J, Shi Y, Glettig M, Feng CH, Frederick DT, Freeman S, Holovatska MM, Manos MP, Zimmer L, Rösch A, Zaremba A, Livingstone E, Jameson JC, Saghafian S, Lee A, Zhao K, Morris LGT, Reardon B, Park J, Elmarakeby HA, Schilling B, Giobbie-Hurder A, Vokes NI, Buchbinder EI, Flaherty KT, Haq R, Wu CJ, Boland GM, Hodi FS, Van Allen EM, Schadendorf D, Liu D. Tarantino G, et al. Among authors: hodi fs. Sci Adv. 2024 Nov 29;10(48):eadp4670. doi: 10.1126/sciadv.adp4670. Epub 2024 Nov 27. Sci Adv. 2024. PMID: 39602539 Free PMC article.
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Khaddour K, Haq R, Buchbinder EI, Liu D, Manos MP, Ott PA, Hodi FS, Insco ML. Khaddour K, et al. Among authors: hodi fs. Oncologist. 2024 Nov 6:oyae297. doi: 10.1093/oncolo/oyae297. Online ahead of print. Oncologist. 2024. PMID: 39504576 Free article.
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
Long GV, Larkin J, Schadendorf D, Grob JJ, Lao CD, Márquez-Rodas I, Wagstaff J, Lebbé C, Pigozzo J, Robert C, Ascierto PA, Atkinson V, Postow MA, Atkins MB, Sznol M, Callahan MK, Topalian SL, Sosman JA, Kotapati S, Thakkar PK, Ritchings C, Pe Benito M, Re S, Soleymani S, Hodi FS. Long GV, et al. Among authors: hodi fs. J Clin Oncol. 2024 Nov 6:JCO2400400. doi: 10.1200/JCO.24.00400. Online ahead of print. J Clin Oncol. 2024. PMID: 39504507
410 results